The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement
Open accessAbstract
Purpose: The primary purposes of eligibility criteria are to protect the safety of trial participants and define the trial population. Excessive or overly restrictive eligibility criteria can slow trial accrual, jeopardize the generalizability of results, and limit understanding of the intervention’s benefit-risk profile. Methods: ASCO, Friends of Cancer Research, and the US Food and Drug Administration examined specific eligibility criteria (ie, brain metastases, minimum age, HIV infection, and organ dysfunction and prior and concurrent malignancies) to determine whether to modify definitions to extend trials to a broader population. Working groups developed consensus recommendations based on review of evidence, consideration of the patient population, and consultation with the research community. Results: Patients with treated or clinically stable brain metastases should be routinely included in trials and only excluded if there is compelling rationale. In initial dose-finding trials, pediatric-specific cohorts should be included based on strong scientific rationale for benefit. Later phase trials in diseases that span adult and pediatric populations should include patients older than age 12 years. HIV-infected patients who are healthy and have low risk of AIDS-related outcomes should be included absent specific rationale for exclusion. Renal function criteria should enable liberal creatinine clearance, unless the investigational agent involves renal excretion. Patients with prior or concurrent malignancies should be included, especially when the risk of the malignancy interfering with either safety or efficacy endpoints is very low. Conclusion: To maximize generalizability of results, trial enrollment criteria should strive for inclusiveness. Rationale for excluding patients should be clearly articulated and reflect expected toxicities associated with the therapy under investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Samji, H., Cescon, A., Hogg, R. S., Modur, S. P., Althoff, K. N., Buchacz, K., Burchell, A. N., Cohen, M., Gebo, K. A., Gill, M. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081355 · Cited by 1,417
Kelly, K., Crowley, J., Bunn, P. A., Presant, C. A., Grevstad, P. K., Moinpour, C. M., Ramsey, S. D., Wozniak, A. J., Weiss, G. R., Moore, D. F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3210 · Cited by 1,123
Systematic Review of Barriers to the Recruitment of Older Patients With Cancer Onto Clinical Trials
Townsley, C. A., Selby, R., & Siu, L. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.141 · Cited by 583
Hurria, A., Dale, W., Mooney, M., Rowland, J. H., Ballman, K. V., Cohen, H. J., Muss, H. B., Schilsky, R. L., Ferrell, B., Extermann, M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0418 · Cited by 362
Self-citationScoggins, J. F., & Ramsey, S. D. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq291 · Cited by 318
The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord, Lewden, C., Bouteloup, V., De Wit, S., Sabin, C., Mocroft, A., Wasmuth, J. C., van Sighem, A., Kirk, O., Obel, N., et al. (2012) · International Journal of Epidemiology · doi:10.1093/ije/dyr164 · Cited by 252
Lichtman, S. M., Harvey, R. D., Damiette Smit, M.-A., Rahman, A., Thompson, M. A., Roach, N., Schenkel, C., Bruinooge, S. S., Cortazar, P., Walker, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.4102 · Cited by 186
Self-citationLin, N., Prowell, T. M., Tan, A. R., Kozak, M., Rosen, O., Amiri‐Kordestani, L., White, J. R., Sul, J., Perkins, L. M., Beal, K., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.0761 · Cited by 132
Self-citationReducing patient eligibility criteria in cancer clinical trials.
George, S. L. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.4.1364 · Cited by 131
Adolescent Dosing and Labeling Since the Food and Drug Administration Amendments Act of 2007
Momper, J. D., Mulugeta, Y. A., Green, D. J., Karesh, A., Krudys, K. M., Sachs, H. C., Yao, L. P., & Burckart, G. J. (2013) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2013.465 · Cited by 116
Modernizing Eligibility Criteria for Molecularly Driven Trials
Kim, E. S., Bernstein, D. S., Hilsenbeck, S. G., Chung, C. H., Dicker, A. P., Ersek, J. L., Stein, S., Khuri, F. R., Burgess, E. F., Hunt, K. K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1854 · Cited by 115
Self-citationImpact of Prior Cancer on Eligibility for Lung Cancer Clinical Trials
Gerber, D. E., Laccetti, A. L., Xuan, L., Halm, E. A., & Pruitt, S. L. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju302 · Cited by 112
Laccetti, A. L., Pruitt, S. L., Xuan, L., Halm, E. A., & Gerber, D. E. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv002 · Cited by 103
Beaver, J. A., Ison, G., & Pazdur, R. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1615879 · Cited by 97
Self-citationGore, L., Ivy, S. P., Balis, F. M., Rubin, E. H., Thornton, K. A., Donoghue, M. B., Roberts, S. A., Bruinooge, S. S., Ersek, J. L., Goodman, N., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.4144 · Cited by 95
Self-citationA Study in Contrasts: Eligibility Criteria in a Twenty-Year Sample of NSABP and POG Clinical Trials
Fuks, A., Weijer, C., Freedman, B., Shapiro, S. H., Skrutkowska, M., & Riaz, A. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(97)00240-0 · Cited by 78
Laccetti, A. L., Pruitt, S. L., Xuan, L., Halm, E. A., & Gerber, D. E. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.05.029 · Cited by 60
Chuk, M. K., Mulugeta, Y. A., Roth-Cline, M. D., Mehrotra, N., & Reaman, G. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1367 · Cited by 56
McCoach, C. E., Berge, E. M., Lu, X. J. D., Barón, A. E., & Camidge, D. R. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.10.024 · Cited by 55
Targeted Therapies in Brain Metastases
Lin, N. (2013) · Current Treatment Options in Neurology · doi:10.1007/s11940-013-0276-z · Cited by 49
Self-citationNaing, A., Rodrigues, H. V., Hong, D. S., Fu, S., Falchook, G. S., Wheler, J. J., Tsimberidou, A. M., Wen, S., Fessahaye, S. N., Golden, E. C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds130 · Cited by 47
Meropol, N. J., Kris, M. G., & Winer, E. P. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.1125 · Cited by 38
Cited by
Review of precision cancer medicine: Evolution of the treatment paradigm
Tsimberidou, A. M., Fountzilas, E., Nikanjam, M., & Kurzrock, R. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102019 · Cited by 756
Unger, J. M., Vaidya, R., Hershman, D. L., Minasian, L. M., & Fleury, M. E. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy221 · Cited by 570
The Magic of Randomization versus the Myth of Real-World Evidence
Collins, R., Bowman, L., Landray, M., & Peto, R. (2020) · New England Journal of Medicine · doi:10.1056/nejmsb1901642 · Cited by 478
Sedrak, M. S., Freedman, R. A., Cohen, H. J., Muss, H. B., Jatoi, A., Klepin, H. D., Wildes, T. M., Le‐Rademacher, J. G., Kimmick, G. G., Tew, W. P., et al. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21638 · Cited by 471
Mao, J. J., Ismaila, N., Bao, T., Barton, D., Ben-Arye, E., Garland, E. L., Greenlee, H., Leblanc, T., Lee, R. T., Lopez, A. M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01357 · Cited by 359
Metadata
- Authors
- Kim, E. S., Bruinooge, S. S., Roberts, S., Ison, G., Lin, N. U., Gore, L., Uldrick, T. S., Lichtman, S. M., Roach, N., Beaver, J. A., Sridhara, R., Hesketh, P. J., Denicoff, A. M., Garrett-Mayer, E., Rubin, E., Multani, P., Prowell, T. M., Schenkel, C., Kozak, M., Allen, J., Sigal, E., & Schilsky, R. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-11-20
- Volume
- 35
- Issue
- 33
- Pages
- 3737-3744
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2763133656
- Cited by
- 485
- References
- 22
- FWCI
- 38.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.